Exhibit K

Case 1:17-cv-12288-GAO Document 68-11 Filed 07/06/18 Page 2 of 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Expires: Dece	mber 31, 2014							
Estimated avera	ge burden							
hours per respon	nse 0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

Print or Type Respo	nses)															
Name and Address of Reporting Person * Sawhney Amarpreet				2. Issuer Name and Ticker or Trading Symbol OCULAR THERAPEUTIX, INC [OCUL]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director _X_ 10% Owner					
(Last) (First) (Middle) C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DRIVE, SUITE 105				3. Date of Earliest Transaction (Month/Day/Year) 12/15/2016							XDirectorX10% Owner _XOfficer (give title below)Other (specify below) President and CEO					
(Street) BEDFORD, MA 01730				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person _ Form filed by More than One Reporting Person					
(City) (State) (Zip)				Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
(Instr. 3) Date (Mon		2. Trans Date (Month/	saction /Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed of (Instr. 3, 4 a		D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership				
						Code	V	Amount	(A) or (D)	Price	(Instr. 3 and 4)	or Indirect (I) (Instr. 4)	(Instr. 4)			
		12/15/	2016		P		45,300	A	\$ 7.85 (1)	677,390	D					
Common Stock											846,377	I	See Footnote			
Common Stock											471,784	I	See Footnote			
Common Stock											379,419	I	See Footnote			
Common Stock										71,969	I	See Footnote (5)				
Common Stock											189,393	I	See Footnote			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information SEC 1474 (9-02) contained in this form are not required to respond unless

the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction	3A. Deemed	4.	5. Number	6. Date Exercisable	7. Title and	8. Price of	9. Number	10.	11. Nature
Derivative	Conversion	Date	Execution Date, if	Transaction	of	and Expiration Date	Amount of	Derivative	of	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)	any	Code	Derivative	(Month/Day/Year)	Underlying	Security	Derivative	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Securities		Securities	(Instr. 5)	Securities	Derivative	Ownership
	Derivative				Acquired		(Instr. 3 and		Beneficially	Security:	(Instr. 4)
	Security				(A) or		4)		Owned	Direct (D)	
					Disposed		, ·		Following	or Indirect	
					of (D)				Reported	(I)	
					(Instr. 3,				Transaction	(Instr. 4)	
					4, and 5)				(s)	`	
					<u> </u>		1		(Instr. 4)		
							Amount		` ′	1	

I	I	Case 1:17-	cv-12288-G	AO I	ρo	cum	en	68-11	Filed	07/	Q6/18	Page	3 of 3	l	l	ı
								Date Exercisable	Expiration	Title	Number					
								Exercisable	Date		of					
				Code	V	(A)	(D)				Shares					

Reporting Owners

B (O N /All	Relationships								
Reporting Owner Name / Address	Director	10% Owner	Officer	Other					
Sawhney Amarpreet C/O OCULAR THERAPEUTIX, INC. 34 CROSBY DRIVE, SUITE 105 BEDFORD, MA 01730	X	X	President and CEO						

Signatures

/s/ Scott LeBlanc, as Attorney-in-Fact for Amarpreet Sawhney	12/16/2016
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 - The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$7.39 to \$8.04, inclusive.
- (1) The reporting person undertakes to provide to Ocular Therapeutix, Inc., any security holder of Ocular Therapeutix, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- (2) The securities are directly held by Incept, LLC. The Reporting Person is a general partner of Incept, LLC. The Reporting Person expressly disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein.
- (3) The securities are directly held by the Sangam Trust. The Reporting Person and his immediate family members are beneficiaries of the Sangam Trust. The Reporting Person expressly disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein.
- (4) The securities are directly held by the SAFIGS Trust. The Reporting Person's immediate family members are beneficiaries of the SAFIGS Trust. The Reporting Person expressly disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein.
- (5) The securities are directly held by the Sawhney Family Dynasty Trust. The Reporting Person's immediate family members are beneficiaries of the Sawhney Family Dynasty Trust. The Reporting Person expressly disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein.
- The securities are directly held by the Amarpreet S. Sawhney 2014 GRAT. The Reporting Person and his immediate family members are beneficiaries of the Amar S. Sawhney 2014 GRAT. The Reporting Person expressly disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.